Skip to main content

Advertisement

Table 2 Impact of difference in medication requirement on relative costs between ICNHD and CvHD

From: Cost analysis of in-centre nocturnal compared with conventional hemodialysis

Resource category CvHD 1($) ICNHD ($) Δ Cost ($, ICNHD – CvHD)
Medication    
Anti-hypertensives 756.00 378.00 (−378.00)
ESAs 6,252.00 3751.20 (−2,500.80)
Bone mineral metabolism medications 1,080.00 540.00 (−540.00)
Reference – no difference in medication use (annual cost/patient) 15,048.28 24,585.86 + 9,537.58
Reduced anti-HTN and bone mineral metabolism medications only (annual cost/patient) 16,884.28 25,503.86 + 8,619.58
Reduced in all medication categories (annual cost/patient) 23,136.28 29,255.06 +6,118.78
  1. 1annual cost of CvHD was informed from the Alberta randomized-controlled trial [11].
  2. Assumptions:
  3. - 50% reduction in number of anti-hypertensives required based on observational studies [1317].
  4. - 40% reduction in required ESA dose based on observational studies [1618].
  5. -50% reduction in amount of bone mineral metabolism medications required based on observational studies [13, 15, 16, 18].
  6. ICNHD: in-centre nocturnal hemodialysis (7 hour sessions, 3x /week, 1:3 staff-to patient ratio); CvHD conventional hemodialysis (4 hour sessions, 3x /week, 1:3 staff-to-patient ratio); ESAs: erythropoiesis-stimulating agents.